Therapeutic potential of turmeric in Alzheimer's disease: Curcumin or curcuminoids?

Phytotherapy Research

Volumn 28, Issue 4, 2014, Pages 517-525

  Ahmed, Touqeer ^a   Gilani, Anwarul Hassan ^b,c  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

^b AGA KHAN UNIVERSITY MEDICAL COLLEGE   (Pakistan)

^c MEKELLE UNIVERSITY   (Ethiopia)

Author keywords

curcumin; curcuminoids; dementia; synergy; therapy; turmeric

Indexed keywords

AZULENE; BETA BISABOLENE; BETA SESQUIPHELLANDRENENDRENE; BORNEOL; CAMPHENE; CARYOPHYLLENE; CINEOLE; CURCUMIN; CURCUMINOID; CURCUMINOID MIXTURE; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; DIHYDROCURCUMIN; DRUG METABOLITE; EUGENOL; FERULIC ACID; HERBACEOUS AGENT; HEXAHYDROCURCUMIN; OCTAHYDROCURCUMIN; OCTANOIC ACID; PIPERINE; TETRAHYDROCURCUMIN; TURMERIC; TURMERONE; UNCLASSIFIED DRUG; ZINGIBERENE;

ALZHEIMER DISEASE; CONTACT DERMATITIS; DEMENTIA; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT;

CURCUMA LONGA;

CURCUMIN; CURCUMINOIDS; DEMENTIA; SYNERGY; THERAPY; TURMERIC;

ALZHEIMER DISEASE; ANIMALS; CURCUMA; CURCUMIN; HUMANS; MOLECULAR STRUCTURE; PHYTOTHERAPY;

EID: 84897986433     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5030     Document Type: Review

References (119)

1. Alzheimer's Association Report. 2011.
2. Aggarwal BB, Sundaram C, Malani N, Ichikawa H,. 2007. Curcumin: the Indian solid gold. Adv Exp Med Biol 595: 1-75.
3. Aggarwal BB, Sung B,. 2009. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30: 85-94.
4. Aggarwal BB, Takada Y, Oommen OV,. 2004. From chemoprevention to chemotherapy: common targets and common goals. Expert Opin Investig Drugs 13: 1327-1338.
5. Ahmed T, Enam SA, Gilani AH,. 2010. Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease. Neuroscience 169: 1296-1306.
6. Ahmed T, Gilani AH,. 2009. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav 91: 554-559.
7. Ahmed T, Gilani AH,. 2011. A comparative study of curcuminoids to measure their effect on inflammatory and apoptotic gene expression in an A beta plus ibotenic acid-infused rat model of Alzheimer's disease. Brain Res 1400: 1-18.
8. Ahmed T, Gilani AH, Hosseinmardi N, Semnanian S, Enam SA, Fathollahi Y,. 2011. Curcuminoids rescue long-term potentiation impaired by amyloid peptide in rat hippocampal slices. Synapse 65: 572-582.
9. Ammon HP, Wahl MA,. 1991. Pharmacology of Curcuma longa. Planta Med 57: 1-7.
10. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S,. 2008. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 70: 445-449.
11. Araujo CC, Leon LL,. 2001. Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz 96: 723-728.
12. Arun N, Nalini N,. 2002. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr 57: 41-52.
13. Avramopoulos D,. 2009. Genetics of Alzheimer's disease: recent advances. Genome Med 1: 34.
14. Azuine MA, Bhide SV,. 1992. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr Cancer 17: 77-83.
15. Babu PS, Srinivasan K,. 1995. Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in albino rat. Mol Cell Biochem 152: 13-21.
16. Bala K, Tripathy BC, Sharma D,. 2006. Neuroprotective and anti-ageing effects of curcumin in aged rat brain regions. Biogerontology 7: 81-89.
17. Baum L, Lam CW, Cheung SK, et al,. 2008. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28: 110-113.
18. Begum AN, Jones MR, Lim GP, et al,. 2008. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 326: 196-208.
19. Bhutani MK, Bishnoi M, Kulkarni SK,. 2009. Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav 92: 39-43.
20. Bisht K, Choi WH, Park SY, Chung MK, Koh WS,. 2009. Curcumin enhances non-inflammatory phagocytic activity of RAW264.7 cells. Biochem Biophys Res Commun 379: 632-636.
21. Blennow K, de Leon MJ, Zetterberg H,. 2006. Alzheimer's disease. Lancet 368: 387-403.
22. Brouet I, Ohshima H,. 1995. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem Biophys Res Commun 206: 533-540.
23. Burns A, Iliffe S,. 2009. Alzheimer's disease. BMJ 338: b158.
24. Burns A, Jacoby R, Levy R,. 1990. Psychiatric phenomena in Alzheimer's disease. IV: disorders of behaviour. Br J Psychiatry 157: 86-94.
25. Cheng AL, Hsu CH, Lin JK, et al,. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900.
26. Dairam A, Limson JL, Watkins GM, Antunes E, Daya S,. 2007. Curcuminoids, curcumin, and demethoxycurcumin reduce lead-induced memory deficits in male Wistar rats. J Agric Food Chem 55: 1039-1044.
27. Deodhar SD, Sethi R, Srimal RC,. 1980. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Ind J Med Res 71: 632-634.
28. Dhillon N, Aggarwal BB, Newman RA, et al,. 2008. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499.
29. Dikshit M, Rastogi L, Shukla R, Srimal RC,. 1995. Prevention of ischaemia-induced biochemical changes by curcumin & quinidine in the cat heart. Ind J Med Res 101: 31-35.
30. Dohare P, Garg P, Jain V, Nath C, Ray M,. 2008. Dose dependence and therapeutic window for the neuroprotective effects of curcumin in thromboembolic model of rat. Behav Brain Res 193: 289-297.
31. Duke JA,. 1992. Handbook of Phytochemical Constituents of GRAS Herbs and Other Economic Plants. CRC Pres: Boca Raton, Florida.
32. Duke JA,. 2002. Hand Book of Medicinal Herbs. CRC Press. Boca Raton, Florida.
33. El-Demerdash FM, Yousef MI, Radwan FM,. 2009. Ameliorating effect of curcumin on sodium arsenite-induced oxidative damage and lipid peroxidation in different rat organs. Food Chem Toxicol 47: 249-254.
34. Fernandez MA, Saenz MT, Garcia MD,. 1998. Anti-inflammatory activity in rats and mice of phenolic acids isolated from Scrophularia frutescens. J Pharm Pharmacol 50: 1183-1186.
35. Ferri CP, Prince M, Brayne C, et al,. 2005. Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
36. Frautschy SA, Hu W, Kim P, et al,. 2001. Phenolic anti-inflammatory antioxidant reversal of A beta-induced cognitive deficits and neuropathology. Neurobiol Aging 22: 993-1005.
37. Ganguli M, Chandra V, Kamboh MI, et al,. 2000. Apolipoprotein E polymorphism and Alzheimer disease: the Indo-US Cross-National Dementia Study. Arch Neurol 57: 824-830.
38. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ,. 2007. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102: 1095-1104.
39. Gilani AH, Atta-ur-Rahman,. 2005. Trends in ethnopharmacology. J Ethnopharmacol 100: 43-49.
40. Gilani AH, Shah AJ, Ghayur MN, Majeed K,. 2005. Pharmacological basis for the use of turmeric in gastrointestinal and respiratory disorders. Life Sci 76: 3089-3105.
41. Govindarajan VS,. 1980. Turmeric-chemistry, technology, and quality. Crit Rev Food Sci Nutr 12: 199-301.
42. Graf E,. 1992. Antioxidant potential of ferulic acid. Free Radic Biol Med 13: 435-448.
43. Hamaguchi T, Ono K, Murase A, Yamada M,. 2009. Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-beta aggregation pathway. Am J Pathol 175: 2557-2565.
44. Hoehle SI, Pfeiffer E, Solyom AM, Metzler M,. 2006. Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver. J Agric Food Chem 54: 756-764.
45. Holder GM, Plummer JL, Ryan AJ,. 1978. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 8: 761-768.
46. Ireson C, Orr S, Jones DJ, et al,. 2001. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61: 1058-1064.
47. Ishrat T, Hoda MN, Khan MB, et al,. 2009. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol 9: 636-647
48. Isik AT, Celik T, Ulusoy G, et al,. 2009. Curcumin ameliorates impaired insulin/IGF signalling and memory deficit in a streptozotocin-treated rat model. Age (Dordr) 31: 39-49.
49. Kapoor L,. 1990. Handbook of Ayurvedic Medicinal Plants. CRC Press: Boca Raton, Florida.
50. Kim DS, Park SY, Kim JK,. 2001. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from beta A(1-42) insult. Neurosci Lett 303: 57-61.
51. Kim H, Park BS, Lee KG, et al,. 2005. Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J Agric Food Chem 53: 8537-8541.
52. Kiso Y, Suzuki Y, Watanabe N, Oshima Y, Hikino H,. 1983. Antihepatotoxic principles of Curcuma longa rhizomes. Planta Med 49: 185-187.
53. Krishnaswamy K,. 2008. Traditional Indian spices and their health significance. Asia Pac J Clin Nutr 17 Suppl 1: 265-268.
54. Kulkarni SK, Bhutani MK, Bishnoi M,. 2008. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology (Berl) 201: 435-442.
55. Kumar P, Padi SS, Naidu PS, Kumar A,. 2007. Possible neuroprotective mechanisms of curcumin in attenuating 3-nitropropionic acid-induced neurotoxicity. Methods Find Exp Clin Pharmacol 29: 19-25.
56. Kurien BT, Scofield RH,. 2009. Increasing aqueous solubility of curcumin for improving bioavailability. Trends Pharmacol Sci 30: 334-335; author reply 335.
57. Lahiri DK, Farlow MR, Greig NH, Sambamurti K,. 2002. Current drug targets for Alzheimer's disease treatment. Drug Dev Res 56: 267-281.
58. Lao CD, Ruffin MTt, Normolle D, et al,. 2006. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6: 10.
59. Li YC, Wang FM, Pan Y, et al,. 2009. Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats. Prog Neuropsychopharmacol Biol Psychiatry 33: 435-449.
60. Liddle M, Hull C, Liu C, Powell D,. 2006. Contact urticaria from curcumin. Dermatitis 17: 196-197.
61. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM,. 2001. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21: 8370-8377.
62. Lin R, Chen X, Li W, Han Y, Liu P, Pi R,. 2008. Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: blockage by curcumin. Neurosci Lett 440: 344-347.
63. Ma QL, Yang F, Rosario ER, et al,. 2009. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29: 9078-9089.
64. May BH, Lit M, Xue CC, et al,. 2009. Herbal medicine for dementia: a systematic review. Phytother Res 23: 447-459.
65. Mishra S, Mishra M, Seth P, Sharma SK,. 2011. Tetrahydrocurcumin confers protection against amyloid beta-induced toxicity. Neuroreport 22: 23-27.
66. Nadkarni KM., 1976. Indian Materia Medica. Popular Prakashan: Bombay.
67. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH,. 2006. Curry consumption and cognitive function in the elderly. Am J Epidemiol 164: 898-906.
68. Nirmala C, Puvanakrishnan R,. 1996. Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 159: 85-93.
69. Ono K, Hasegawa K, Naiki H, Yamada M,. 2004. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 75: 742-750.
70. Ono K, Hirohata M, Yamada M,. 2005. Ferulic acid destabilizes preformed beta-amyloid fibrils in vitro. Biochem Biophys Res Commun 336: 444-449.
71. Ozaki Y., 1992. Antiinflammatory effect of tetramethylpyrazine and ferulic acid. Chem Pharm Bull (Tokyo) 40: 954-956.
72. Pae HO, Jeong SO, Zheng M, et al,. 2009. Curcumin attenuates ethanol-induced toxicity in HT22 hippocampal cells by activating mitogen-activated protein kinase phosphatase-1. Neurosci Lett 453: 186-189.
73. Pan MH, Huang TM, Lin JK,. 1999. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27: 486-494.
74. Pan R, Qiu S, Lu DX, Dong J,. 2008. Curcumin improves learning and memory ability and its neuroprotective mechanism in mice. Chin Med J (Engl) 121: 832-839.
75. Park SY, Kim DS,. 2002. Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer's disease. J Nat Prod 65: 1227-1231.
76. Park SY, Kim HS, Cho EK, et al,. 2008. Curcumin protected PC12 cells against beta-amyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation. Food Chem Toxicol 46: 2881-2887.
77. Perkins S, Verschoyle RD, Hill K, et al,. 2002. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 11: 535-540.
78. Qin NY, Yang FQ, Wang YT, Li SP,. 2007. Quantitative determination of eight components in rhizome (Jianghuang) and tuberous root (Yujin) of Curcuma longa using pressurized liquid extraction and gas chromatography-mass spectrometry. J Pharm Biomed Anal 43: 486-492.
79. Quitschke WW,. 2008. Differential solubility of curcuminoids in serum and albumin solutions: implications for analytical and therapeutic applications. BMC Biotechnol 8: 84.
80. Qureshi S, Shah AH, Ageel AM,. 1992. Toxicity studies on Alpinia galanga and Curcuma longa. Planta Med 58: 124-127.
81. Rajakrishnan V, Viswanathan P, Rajasekharan KN, Menon VP,. 1999. Neuroprotective role of curcumin from Curcuma longa on ethanol-induced brain damage. Phytother Res 13: 571-574.
82. Rajeswari A,. 2006. Curcumin protects mouse brain from oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Eur Rev Med Pharmacol Sci 10: 157-161.
83. Rastogi M, Ojha RP, Rajamanickam GV, Agrawal A, Aggarwal A, Dubey GP,. 2008. Curcuminoids modulates oxidative damage and mitochondrial dysfunction in diabetic rat brain. Free Radic Res 42: 999-1005.
84. Rasyid A, Lelo A,. 1999. The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 13: 245-249.
85. Rasyid A, Rahman AR, Jaalam K, Lelo A,. 2002. Effect of different curcumin dosages on human gall bladder. Asia Pac J Clin Nutr 11: 314-318.
86. Ringman JM, Younkin SG, Pratico D, et al,. 2008. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71: 85-92.
87. Sandur SK, Pandey MK, Sung B, et al,. 2007. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 28: 1765-1773.
88. Scott BC, Butler J, Halliwell B, Aruoma OI,. 1993. Evaluation of the antioxidant actions of ferulic acid and catechins. Free Radic Res Commun 19: 241-253.
89. Selvam C, Jachak SM, Thilagavathi R, Chakraborti AK,. 2005. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett 15: 1793-1797.
90. Sethi P, Jyoti A, Hussain E, Sharma D,. 2009. Curcumin attenuates aluminium-induced functional neurotoxicity in rats. Pharmacol Biochem Behav 93: 31-39.
91. Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS,. 1980. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guinea pigs & monkeys. Indian J Exp Biol 18: 73-75.
92. Sharma D, Sethi P, Hussain E, Singh R,. 2009a. Curcumin counteracts the aluminium-induced ageing-related alterations in oxidative stress, Na(+), K(+) ATPase and protein kinase C in adult and old rat brain regions. Biogerontology 10: 489-502.
93. Sharma S, Zhuang Y, Ying Z, Wu A, Gomez-Pinilla F,. 2009b. Dietary curcumin supplementation counteracts reduction in levels of molecules involved in energy homeostasis after brain trauma. Neuroscience 161: 1037-1044.
94. Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H,. 2008. Epigallocatechin-3-gallate and curcumin suppress amyloid beta-induced beta-site APP cleaving enzyme-1 upregulation. Neuroreport 19: 1329-1333.
95. Shishu, Maheshwari M,. 2010. Comparative bioavailability of curcumin, turmeric and Biocurcumax™ in traditional vehicles using non-everted rat intestinal sac model. J Functional Foods 2: 60-65.
96. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS,. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356.
97. Shukla PK, Khanna VK, Khan MY, Srimal RC,. 2003. Protective effect of curcumin against lead neurotoxicity in rat. Hum Exp Toxicol 22: 653-658.
98. Shytle RD, Tan J, Bickford PC, et al,. 2012. Optimized turmeric extract reduces beta-amyloid and phosphorylated tau protein burden in Alzheimer's transgenic mice. Curr Alzheimer Res 9: 500-506.
99. Sreejayan, Rao MN,. 1994. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 46: 1013-1016.
100. Sreejayan, Rao MN,. 1997. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol 49: 105-107.
101. Srinivasan M,. 1972. Effect of curcumin on blood sugar as seen in a diabetic subject. Ind J Med Sci 26: 269-270.
102. Srivastava R, Dikshit M, Srimal RC, Dhawan BN,. 1985. Anti-thrombotic effect of curcumin. Thromb Res 40: 413-417.
103. Suh YH, Checler F,. 2002. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev 54: 469-525.
104. Tang H, Lu D, Pan R, Qin X, Xiong H, Dong J,. 2009. Curcumin improves spatial memory impairment induced by human immunodeficiency virus type 1 glycoprotein 120 V3 loop peptide in rats. Life Sci 85: 1-10.
105. Vagnucci AH, Jr., Li WW,. 2003. Alzheimer's disease and angiogenesis. Lancet 361: 605-608.
106. Venkatesan N,. 1998. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 124: 425-427.
107. Wahlstrom B, Blennow G,. 1978. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 43: 86-92.
108. Wang R, Li YB, Li YH, Xu Y, Wu HL, Li XJ,. 2008. Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB. Brain Res 1210: 84-91.
109. Wang YJ, Thomas P, Zhong JH, et al,. 2009. Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. Neurotox Res 15: 3-14.
110. Xiong Z, Hongmei Z, Lu S, Yu L,. 2011. Curcumin mediates presenilin-1 activity to reduce beta-amyloid production in a model of Alzheimer's disease. Pharmacol Rep 63: 1101-1108.
111. Yang F, Lim GP, Begum AN, et al,. 2005. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280: 5892-5901.
112. Yousef MI, El-Demerdash FM, Radwan FM,. 2008. Sodium arsenite induced biochemical perturbations in rats: ameliorating effect of curcumin. Food Chem Toxicol 46: 3506-3511.
113. Yu ZF, Kong LD, Chen Y,. 2002. Antidepressant activity of aqueous extracts of Curcuma longa in mice. J Ethnopharmacol 83: 161-165.
114. Zeng Y, Qiu F, Liu Y, Qu G, Yao X,. 2007. Isolation and identification of phase 1 metabolites of demethoxycurcumin in rats. Drug Metab Dispos 35: 1564-1573.
115. Zhang C, Browne A, Child D, Tanzi RE,. 2010a. Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem 285: 28472-28480.
116. Zhang L, Fiala M, Cashman J, et al,. 2006. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. J Alzheimers Dis 10: 1-7.
117. Zhang L, Wu C, Zhao S, et al,. 2010b. Demethoxycurcumin, a natural derivative of curcumin attenuates LPS-induced pro-inflammatory responses through down-regulation of intracellular ROS-related MAPK/NF-kappaB signaling pathways in N9 microglia induced by lipopolysaccharide. Int Immunopharmacol 10: 331-338.
118. Zhang LJ, Wu CF, Meng XL, et al,. 2008. Comparison of inhibitory potency of three different curcuminoid pigments on nitric oxide and tumor necrosis factor production of rat primary microglia induced by lipopolysaccharide. Neurosci Lett 447: 48-53.
119. Zhao J, Zhao Y, Zheng W, Lu Y, Feng G, Yu S,. 2008. Neuroprotective effect of curcumin on transient focal cerebral ischemia in rats. Brain Res 1229: 224-232.